Standard Chartered initiated Morpho coverage with a $60 end-2030 target, implying about 2,787% upside from levels above $2. Its forecast path puts MORPHO at $3.50 in 2026, $11 in 2027, $22 in 2028, $40 in 2029 and $60 in 2030.
Source: Read the original article

